Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene

Cancer Cell

Volumn 2, Issue 1, 2002, Pages 67-79

  Watson, Philip A ^a   Kim, Kwanghee ^a   Chen, Kai Shun ^a   Gould, Michael N ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TESTOSTERONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOGENESIS; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CROSS; GONADECTOMY; MALE; MAMMARY GLAND; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RAT; TRANSGENE; AGING; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE AMPLIFICATION; GENETICS; NEOPLASM; ORCHIECTOMY; OVARIECTOMY; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; TRANSGENIC ANIMAL; UDDER;

AGING; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TESTOSTERONE; TIME FACTORS;

EID: 0036652154     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00083-1     Document Type: Article

References (63)

1. Allegra, J.C., Lippman, M.E., Thompson, E.B., Simon, R., Barlock, A., Green, L., Huff, K.K., Do, H.M., and Aitken, S.C. (1979). Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 39, 1447-1454.
2. Bargmann, C.I., Hung, M.C., and Weinberg, R.A. (1986). Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
3. Bargmann, C.I., and Weinberg, R.A. (1988). Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA 85, 5394-5398.
4. Berger, M.S., Locher, G.W., Saurer, S., Gullick, W.J., Waterfield, M.D., Groner, B., and Hynes, N.E. (1988). Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48, 1238-1243.
5. Berns, E.M., Klijn, J.G., van Staveren, I.L, Portengen, H., Noordegraaf, E., and Foekens, J.A. (1992). Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur. J. Cancer 28, 697-700.
6. Berrino, F., Muti, P., Micheli, A., Bolelli, G., Krogh, V., Sciajno, R., Pisani, P., Panico, S., and Secreto, G. (1996). Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. 88, 291-296.
7. Bouchard, L., Lamarre, L., Tremblay, P.J., and Jolicoeur, P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57, 931-936.
8. Bruce, D.M., Heys, S.D., Payne, S., Miller, I.D., and Eremin, O. (1996). Male breast cancer - clinico-pathological features, immunocytochemical characteristics and prognosis. Eur. J. Surg. Oncol. 22, 42-46.
9. Burrows, H. (1949). The action of androgen on the reproductive organs after their complete differentiation. In Biological Actions of Sex Hormones, H. Burrows, ed. (Cambridge, UK: Cambridge University Press), pp. 220-225.
10. Cauley, J.A., Lucas, F.L., Kuller, L.H., Stone, K., Browner, W., and Cummings, S.R. (1999). Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann. Intern. Med. 130, 270-277.
11. Charreau, B., Tesson, L., Soulillou, J.P., Pourcel, C., and Anegon, I. (1996). Transgenesis in rats - technical aspects and models. Transgenic Res. 5, 223-234.
12. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648.
13. Craft, N., Shostak, Y., Carey, M., and Sawyers, C.L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285.
14. Davies, B.R., Warren, J.R., Schmidt, G., and Rudland, P.S. (1998). Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats. Biochem. Soc. Symp. 63, 167-184.
15. Davies, B.R., Platt-Higgins, A.M., Schmidt, G., and Rudland, P.S. (1999). Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFα transgenic rats. Am. J. Pathol. 155, 303-314.
16. Dawson, P.J., Paine, T.M., and Wolman, S.R. (1992). Immunocytochemical characterization of male breast cancer. Mod. Pathol. 5, 621-625.
17. Dorgan, J.F., Longcope, C., Stephenson, H.E., Falk, R.T., Miller, R., Franz, C., Kahle, L., Campbell, W.S., Tangrea, J.A., and Schatzkin, A. (1996). Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 5, 533-539.
18. Guy, C.T., Webster, M.A., Schaller, M., Parsons, T.J., Cardiff, R.D., and Muller, W.J. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10578-10582.
19. Hall, R.E., Clements, J.A., Birrell, S.N., and Tilley, W.D. (1998). Prostatespecific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br. J. Cancer 78, 360-365.
20. Heng, H.H., and Tsui, L.C. (1993). Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma 102, 325-332.
21. Heng, H.H., Squire, J., and Tsui, L.C. (1992). High-resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc. Natl. Acad. Sci. USA 89, 9509-9513.
22. Isola, J.J. (1993). Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170, 31-35.
23. Ito, I., Yoshimoto, M., Iwase, T., Watanabe, S., Katagiri, T., Harada, Y., Kasumi, F., Yasuda, S., Mitomi, T., Emi, M., and Nakamura, Y. (1995). Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br. J. Cancer 71, 438-441.
24. Joshi, M.G., Lee, A.K.C., Loda, M., Camus, M.G., Pedersen, C., Heatley, G.J., and Hughes, K.S. (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77, 490-498.
25. Koelsch, B.U. (1998). Assignment of erbB2 to rat chromosome band 10q32.1 by in situ hybridization. Cytogenet. Cell Genet. 81, 182.
26. Kollara, A., Kahn, H.J., Marks, A., and Brown, T.J. (2001). Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res. Treat. 67, 245-253.
27. Lea, O.A., Kvinnsland, S., and Thorsen, T. (1989). Improved measurement of androgen receptors in human breast cancer. Cancer Res. 49, 7162-7167.
28. Lemoine, N.R., Staddon, S., Dickson, C., Barnes, D.M., and Gullick, W.J. (1990). Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5, 237-239.
29. Liao, D.Z.J., Pantazis, C.G., Hou, X.Y., and Li, S.A. (1998). Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 19, 2173-2180.
30. Miller, W.R., Telford, J., Dixon, J.M., and Hawkins, R.A. (1985). Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur. J. Cancer Clin. Oncol. 21, 539-542.
31. Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
32. Nandi, S., Guzman, R.C., and Yang, J. (1995). Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA 92, 3650-3657.
33. Osman, I., Scher, H.I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J.S., and Cordon-Cardo, C. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 7, 2643-2647.
34. Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L., Gorman, C.M., Parker, M.G., Sliwkowski, M.X., and Slamon, D.J. (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-2446.
35. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996). Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467.
36. Quenel, N., Wafflart, J., Bonichon, F., de Mascarel, I., Trojani, M., Durand, M., Avril, A., and Coindre, J.M. (1995). The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat. 35, 283-291.
37. Ravandi-Kashani, F., and Hayes, T.G. (1998). Male breast cancer: a review of the literature. Eur. J. Cancer 34, 1341-1347.
38. Rayson, D., Erlichman, C., Suman, V.J., Roche, P.C., Wold, L.E., Ingle, J.N., and Donohue, J.H. (1998). Molecular markers in male breast carcinoma. Cancer 83, 1947-1955.
39. Read, L.D., Keith, D., Slamon, D.J., and Katzenellenbogen, B.S. (1990). Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 50, 3947-3951.
40. Reese, D.M., Small, E.J., Magrane, G., Waldman, F.M., Chew, K., and Sudilovsky, D. (2001). HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am. J. Clin. Pathol. 116, 234-239.
41. Shi, Y., Brands, F.H., Chatterjee, S., Feng, A.C., Groshen, S., Schewe, J., Lieskovsky, G., and Cote, R.J. (2001). HER-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol. 166, 1514-1519.
42. Shpitz, B., Bomstein, Y., Sternberg, A., Klein, E., Liverant, S., Groisman, G., and Bernheim, J. (2000). Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J. Surg. Oncol. 75, 252-257.
43. Siegel, P.M., and Muller, W.J. (1996). Mutations affecting conserved cysteine residues within the extracellular domain of neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. USA 93, 8878-8883.
44. Siegel, P.M., Dankort, D.L., Hardy, W.R., and Muller, W.J. (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068-7077.
45. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., et al. (2000). HER-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925.
46. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
47. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
48. Suda, Y., Aizawa, S., Furuta, Y., Yagi, T., Ikawa, Y., Saitoh, K., Yamada, Y., Toyoshima, K., and Yamamoto, T. (1990). Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659 → Glu659). EMBO J. 9, 181-190.
49. Temmim, L., Luqmani, Y.A., Jarallah, M., Juma, I., and Mathew, M. (2001). Evaluation of prognostic factors in male breast cancer. Breast 10, 166-175.
50. Thomas, H.V., Key, T.J., Allen, D.S., Moore, J.W., Dowsett, M., Fentiman, I.S., and Wang, D.Y. (1997). A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br. J. Cancer 76, 401-405.
51. Thompson, T.A., and Gould, M.N. (2000). Direct gene transfer into the mammary epithelium in situ using retroviral vectors. In Methods in Mammary Gland Biology and Breast Cancer Research, M.M. Ip, and B.B. Asch, eds. (New York: Kluwer Academic/Plenum Publishers), pp. 245-257.
52. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., et al. (2001). First-line Herceptin® monotherapy in metastatic breast cancer. Oncology 61 (Suppl. 2), 37-42.
53. Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1991a). Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res. 51, 5649-5654.
54. Wang, B.C., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1991b). Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. Cancer Res. 51, 2642-2648.
55. Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1992). Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. Cancer Res. 52, 4102-4105.
56. Weiner, D.B., Liu, J., Cohen, J.A., Williams, W.V., and Greene, M.I. (1989). A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339, 230-231.
57. Wen, Y., Hu, M.C.T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.H., and Hung, M.C. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6841-6845.
58. Willsher, P.C., Leach, I.H., Ellis, I.O., Bell, J.A., Elston, C.W., Bourke, J.B., Blarney, R.W., and Robertson, J.F.R. (1997). Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 17, 2335-2338.
59. Xie, B., Tsao, S.W., and Wong, Y.C. (1999). Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone. Carcinogenesis 20, 1069-1078.
60. Yarden, Y. (1990). Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA 87, 2569-2573.
61. Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology 61 (Suppl. 2), 1-13.
62. Yeh, S.Y., Lin, H.K., Kang, H.Y., Thin, T.H., Lin, M.F., and Chang, C.S. (1999). From HER2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96, 5458-5463.
63. Zeillinger, R., Kury, F., Czerwenka, K., Kubista, E., Sliutz, G., Knogler, W., Huber, J., Zielinski, C., Reiner, G., Jakesz, R., et al. (1989). HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4, 109-114.